Prostate neuroendocrine neoplasm
MONDO:0002477A neoplasm with neuroendocrine differentiation that arises from the prostate gland. This category includes carcinoid tumors and small cell carcinomas.
Also known as: neuroendocrine neoplasm of prostate, neuroendocrine neoplasm of prostate gland, neuroendocrine neoplasm of the prostate, neuroendocrine tumour of the prostate, prostate gland NET, prostate gland neuroendocrine neoplasm, prostate gland neuroendocrine tumor, prostate gland neuroendocrine tumor, well differentiated, low or intermediate grade
1479 clinical trials for this condition and its sub-types, 20 tagged with Prostate neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Prostate neuroendocrine neoplasm
-
Prostate small cell carcinoma 9 trials
-
New drug takes aim at hard-to-treat neuroendocrine prostate cancer
Disease control Not yet recruitingThis phase 2 trial tests a drug called sacituzumab tirumotecan in people with neuroendocrine prostate cancer, a rare and aggressive form that has progressed after platinum-based chemotherapy. The drug is given by IV infusion three times per 42-day cycle. The study measures how ma…
Phase 2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New radiation drug targets tough cancers in early trial
Disease control Not yet recruitingThis early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a memory drug fight prostate cancer? small trial aims to find out
Disease control Not yet recruitingThis phase 2 trial tests whether memantine hydrochloride, a drug used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard hormone therapy. Fifteen men with metastatic castration-resistant prostate cancer will take memantine alongside…
Phase 2 • Sponsor: Bin Xu • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC